MEGALiT - a Multicenter, Basket and Umbrella Explorative Trial on the Efficacy and Safety of Molecular Profile Selected Commercially Available Targeted Anti-cancer Drugs in Patients With Advanced Cancers Progressive on Standard Therapy
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 167
- 试验地点
- 3
- 主要终点
- Objective Response Rate (ORR) and tumor control rate [Time Frame: From first dose up to 24 months]
研究概览
简要总结
This is a prospective, open-label, non-randomized combined basket- and umbrella trial divided in two parts; a limited feasibility-oriented part 1 including 154 patients and 3 treatment cohorts and part 2 that will include an expanded cohort of patients and treatment cohorts. The overall aims of the study are to test the feasibility, safety and efficacy of comprehensive genomic profiling on fresh tumor biopsies as a basis for treatment decision making and to compare two different sequencing, bioinformatics and decision-making platforms (part 1). Also to evaluate the efficacy and safety of off-label treatment with cancer drugs in patients selected based on genomic biomarker matching.
详细描述
This is a prospective, open-label, non-randomized combined basket- and umbrella trial divided in two parts; a limited feasibility-oriented part 1 including 154 patients and 3 treatment cohorts (mutation/drug) and part 2 that will include an expanded cohort of patients and treatment cohorts. The overall aims of the study are to test the feasibility, safety and efficacy of comprehensive genomic profiling on fresh tumor biopsies as a basis for treatment decision making and to compare two different sequencing, bioinformatics and decision-making platforms (part 1). Also to evaluate the efficacy and safety of off-label treatment with cancer drugs in patients selected based on genomic biomarker matching.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult (age >18 years)
- •Patients with histologically-proven, locally advanced or metastatic solid tumor (part 1; hematological malignancies also eligible in part 2) progressive while on last line established therapy considered available for the patient. For re-recruitment (part 2) patients must be progressive while on trial defined treatment or off-protocol treatment.
- •Fresh tumor sampling by biopsy must be possible, except for patients with CNS malignancy who can be included based on molecular analysis of archived tumor material.
- •ECOG performance status 0-
- •Patients must have acceptable organ function as defined below:
- •Absolute neutrophil count ≥ 1.5 x 10^9/L
- •Hemoglobin > 90 g/L
- •Platelets > 75 x 10^9/L
- •Total bilirubin < 2 x ULN
- •ASAT (SGOT) and ALAT (SGPT) < 2.5 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
- •Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
- •Patients must have objectively measurable disease (by physical or radiographic examination).
- •Ability to understand and the willingness to sign a written informed consent document.
- •For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
- •Negative pregnancy test in women of childbearing potential (premenopausal or <12 months of amenorrhea post-menopause and who have not undergone surgical sterilization). Women of childbearing potential must use highly effective method of contraception, i.e. combined hormonal contraception, or progestogen-only hormonal contraception, or intrauterine device, or intrauterine hormone-releasing system, or bilateral tubal occlusion, or vasectomized partner, or sexual abstinence for the duration of participation in the study, and four months following completion of study therapy.
- •Selected tumor types might have disease-specific inclusion criteria, defined by disease-specific study appendix.
排除标准
- •Ongoing treatment-related toxicity > grade
- •Patients receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates, somatostatin analogues and prednisone, or equivalent, >5 mg/d). These medications must have been started ≥ 1 week prior to the screening visit on this study. Radiotherapy to non-target lesions is allowed.
- •Patients pregnant or nursing.
- •Patients of childbearing potential and sexually active and not willing to use highly effective contraceptive.
- •Patients with known active progressive CNS metastases. Patients with previously treated CNS metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to inclusion. All patients with previously treated CNS metastases must be stable for at least 1 month after completion of treatment and off steroid treatment prior to inclusion.
- •Some concomitant diseases qualified for exclusion as detailed in main protocol.
- •Other serious underlying medical conditions, which, in the Investigator's judgment, could impair the ability of the patient to participate in the trial.
研究组 & 干预措施
Mutation burden
Atezolizumab. 1200mg iv every 3 weeks.
干预措施: Atezolizumab (Drug)
NF1/MAP2K1
Cobimetinib, 60mg po daily. 28 day cycle; day 1-21 60mg daily, day 22-28 rest period.
干预措施: Cobimetinib (Drug)
MTOR/TSC1/TSC2
Everolimus, 10mg po daily.
干预措施: Everolimus (Drug)
PPARi
Niraparib. 300mg po daily.
干预措施: Niraparib (Drug)
结局指标
主要结局
Objective Response Rate (ORR) and tumor control rate [Time Frame: From first dose up to 24 months]
时间窗: 1 year follow-up after LPFV
The proportion of patients that have a best overall response of complete response (CR), partial response (PR) or stable disease ≥16 weeks, as assessed by RECIST 1.1 criteria
次要结局
- Additional measurements of treatment efficacy(1 year follow-up after LPFV)
- Drug-related safety, evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03(1 year follow-up after LPFV)
- Overall survival(1 year follow-up after LPFV)
- Feasibility of study design(1 year follow-up after LPFV)
- Biopsy safety: NCI Common Terminology Criteria for Adverse Events 4.03 as grade 3 - 4 adverse event related to the procedure(1 year follow-up after LPFV)
- Genomic analysis(1 year follow-up after LPFV)
研究者
Peter Nygren
MD, PhD, professor in oncology
Uppsala University Hospital